Skip to main content
Erschienen in: Journal of Gastroenterology 2/2011

01.02.2011 | Original Article—Alimentary Tract

DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness

verfasst von: Yuji Toiyama, Yasuhiro Inoue, Hiromi Yasuda, Susumu Saigusa, Takeshi Yokoe, Yoshinaga Okugawa, Koji Tanaka, Chikao Miki, Masato Kusunoki

Erschienen in: Journal of Gastroenterology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

We investigated changes in the gene expression profile in colon cancer in order to identify gene markers that may be useful in the management of this disease.

Methods

The Cancer Genome Anatomy Project was used to detect differences in gene expression between normal and cancer tissue. The overexpression of dipeptidase-1 (DPEP1) in cancer tissue was confirmed in a sample of 76 patients by real-time PCR. To identify the function of DPEP1, RNA interference (RNAi) was used to inactivate this gene in the colon cancer cell line. Immunohistochemical analysis was performed to characterize the pattern of DPEP1 expression in colon cancer.

Results

DPEP1 expression in cancer was significantly higher than that in normal tissue. However, DPEP1 expression decreased with pathological differentiation, lymph-node and distant metastasis. Patients with tumors with decreased DPEP1 expression showed a poorer prognosis, and this was also true of patients with tumors who are treated with curative intent. RNAi-mediated DPEP1 reduction in the colon cancer cell line did not result in cell proliferation or apoptosis, but was associated with an increased invasive ability. DPEP1 protein was observed on the apical side of the cancer cells, and is expressed in the early stages of carcinogenesis, even in adenomas of both sporadic colorectal cancer and familial adenomatous polyposis patients.

Conclusions

DPEP1 expression in normal colonic mucosa is very low, but it is highly expressed in colorectal adenoma and cancer specimens and is negatively correlated with parameters of pathological aggressiveness and poor prognosis. DPEP1 is expressed in the early stages of colon carcinogenesis and affects cancer cell invasiveness.
Literatur
1.
Zurück zum Zitat Messerini L, Cianchi F, Cortesini C, Comin CE. Incidence and prognostic significance of occult tumor cells in lymph nodes from patients with stage IIA colorectal carcinoma. Hum Pathol. 2006;37:1259–67.CrossRefPubMed Messerini L, Cianchi F, Cortesini C, Comin CE. Incidence and prognostic significance of occult tumor cells in lymph nodes from patients with stage IIA colorectal carcinoma. Hum Pathol. 2006;37:1259–67.CrossRefPubMed
2.
Zurück zum Zitat Shih W, Chetty R, Tsao MS. Expression profiling by microarrays in colorectal cancer (review). Oncol Rep. 2005;13:517–24. Shih W, Chetty R, Tsao MS. Expression profiling by microarrays in colorectal cancer (review). Oncol Rep. 2005;13:517–24.
3.
Zurück zum Zitat Tsukuma H, Ajiki W, Oshima A. Cancer incidence in Japan. Gan To Kagaku Ryoho. 2004;31:840–6.PubMed Tsukuma H, Ajiki W, Oshima A. Cancer incidence in Japan. Gan To Kagaku Ryoho. 2004;31:840–6.PubMed
4.
Zurück zum Zitat Houlston RS. What we could do now: molecular pathology of colorectal cancer. Mol Pathol. 2001;54:206–14.CrossRefPubMed Houlston RS. What we could do now: molecular pathology of colorectal cancer. Mol Pathol. 2001;54:206–14.CrossRefPubMed
5.
Zurück zum Zitat Haydon AMM, Jass JR. Emerging pathways in colorectal cancer development. Lancet. 2002;3:83–8.CrossRef Haydon AMM, Jass JR. Emerging pathways in colorectal cancer development. Lancet. 2002;3:83–8.CrossRef
6.
Zurück zum Zitat Strausberg RL. The cancer genome anatomy project: new resources for reading the molecular signatures of cancer. J Pathol. 2001;195:31–40.CrossRefPubMed Strausberg RL. The cancer genome anatomy project: new resources for reading the molecular signatures of cancer. J Pathol. 2001;195:31–40.CrossRefPubMed
7.
Zurück zum Zitat Kozak EM, Tate SS. Glutathione-degrading enzymes of microvillus membranes. J Biol Chem. 1982;257:6322–7.PubMed Kozak EM, Tate SS. Glutathione-degrading enzymes of microvillus membranes. J Biol Chem. 1982;257:6322–7.PubMed
8.
Zurück zum Zitat Hooper NM, Low MG, Turner AJ. Renal dipeptidase is one of the membrane proteins released by phosphatidylinositol-specific phospholipase C. Biochem J. 1987;244:465–9.PubMed Hooper NM, Low MG, Turner AJ. Renal dipeptidase is one of the membrane proteins released by phosphatidylinositol-specific phospholipase C. Biochem J. 1987;244:465–9.PubMed
9.
Zurück zum Zitat Adachi H, Tawaragi Y, Inuzuka C, Kubota I, Tsujimoto M, Nishihara T, et al. Primary structure of human microsomal dipeptidase deduced from molecular cloning. J Biol Chem. 1990;265:3992–5.PubMed Adachi H, Tawaragi Y, Inuzuka C, Kubota I, Tsujimoto M, Nishihara T, et al. Primary structure of human microsomal dipeptidase deduced from molecular cloning. J Biol Chem. 1990;265:3992–5.PubMed
10.
Zurück zum Zitat McIver CM, Lloyd JM, Hewett PJ, Hardingham JE. Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett. 2004;209:67–74.CrossRefPubMed McIver CM, Lloyd JM, Hewett PJ, Hardingham JE. Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett. 2004;209:67–74.CrossRefPubMed
11.
Zurück zum Zitat Yajima S, Ishii M, Matsushita H, Aoyagi K, Yoshimatsu K, Kaneko H, et al. Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer. Int J Oncol. 2007;31:1029–37.PubMed Yajima S, Ishii M, Matsushita H, Aoyagi K, Yoshimatsu K, Kaneko H, et al. Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer. Int J Oncol. 2007;31:1029–37.PubMed
12.
Zurück zum Zitat Aster VB, Coller FA. The prognosis significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954;192:846–50.CrossRef Aster VB, Coller FA. The prognosis significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954;192:846–50.CrossRef
13.
Zurück zum Zitat Austruy E, Cohen-Salmon M, Antignac C, Béroud C, Henry I, Nguyen VC, et al. Isolation of kidney complementary DNAs down-expressed in Wilms’ tumor by a subtractive hybridization approach. Cancer Res. 1993;53:2888–94.PubMed Austruy E, Cohen-Salmon M, Antignac C, Béroud C, Henry I, Nguyen VC, et al. Isolation of kidney complementary DNAs down-expressed in Wilms’ tumor by a subtractive hybridization approach. Cancer Res. 1993;53:2888–94.PubMed
14.
Zurück zum Zitat Nakagawa H, Inazawa J, Inoue K, Misawa S, Kashima K, Adachi H, et al. Assignment of the human renal dipeptidase gene (DPEP1) to band q24 of chromosome 16. Cytogenet Cell Genet. 1991;59:258–60.CrossRef Nakagawa H, Inazawa J, Inoue K, Misawa S, Kashima K, Adachi H, et al. Assignment of the human renal dipeptidase gene (DPEP1) to band q24 of chromosome 16. Cytogenet Cell Genet. 1991;59:258–60.CrossRef
15.
Zurück zum Zitat Austruy E, Jeanpierre C, Antignac C, Whitmore SA, Van Cong N, Bernheim A, et al. Physical and genetic mapping of the dipeptidase gene DPEP1 to 16q24.3. Genomics. 1993;15:684–7.CrossRefPubMed Austruy E, Jeanpierre C, Antignac C, Whitmore SA, Van Cong N, Bernheim A, et al. Physical and genetic mapping of the dipeptidase gene DPEP1 to 16q24.3. Genomics. 1993;15:684–7.CrossRefPubMed
16.
Zurück zum Zitat Godfrey TE, Cher ML, Chhabra V, Jensen RH. Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Cancer Genet Cytogenet. 1997;98:36–42.CrossRefPubMed Godfrey TE, Cher ML, Chhabra V, Jensen RH. Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma. Cancer Genet Cytogenet. 1997;98:36–42.CrossRefPubMed
17.
Zurück zum Zitat Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Tajiri T, et al. Identification of a 1-Mb common region at 16q24.1–24.2 deleted in hepatocellular carcinoma. Genes Chromosomes Cancer. 2000;28:38–44.CrossRefPubMed Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Tajiri T, et al. Identification of a 1-Mb common region at 16q24.1–24.2 deleted in hepatocellular carcinoma. Genes Chromosomes Cancer. 2000;28:38–44.CrossRefPubMed
18.
Zurück zum Zitat Sato M, Mori Y, Sakurada A, Fukushige S, Ishikawa Y, Tsuchiya E, et al. Identification of a 910-kb region of common allelic loss in chromosome bands 16q24.1–q24.2 in human lung cancer. Genes Chromosomes Cancer. 1998;22:1–8.CrossRefPubMed Sato M, Mori Y, Sakurada A, Fukushige S, Ishikawa Y, Tsuchiya E, et al. Identification of a 910-kb region of common allelic loss in chromosome bands 16q24.1–q24.2 in human lung cancer. Genes Chromosomes Cancer. 1998;22:1–8.CrossRefPubMed
19.
Zurück zum Zitat Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol. 1999;15:715–20.PubMed Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol. 1999;15:715–20.PubMed
20.
Zurück zum Zitat Rakha EA, Green AR, Powe DG, Roylance R, Ellis IO. Chromosome 16 tumor-suppressor genes in breast cancer. Genes Chromosomes Cancer. 2006;45:527–35.CrossRefPubMed Rakha EA, Green AR, Powe DG, Roylance R, Ellis IO. Chromosome 16 tumor-suppressor genes in breast cancer. Genes Chromosomes Cancer. 2006;45:527–35.CrossRefPubMed
21.
Zurück zum Zitat Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science. 1989;244:207–11.CrossRefPubMed Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science. 1989;244:207–11.CrossRefPubMed
22.
Zurück zum Zitat Weber TK, Conroy J, Keitz B, Rodriguez-Bigas M, Petrelli NJ, Stoler DL, et al. Genome-wide allelotyping indicates increased loss of heterozygosity on 9p and 14q in early age of onset colorectal cancer. Cytogenet Cell Genet. 1999;86:142–7.CrossRefPubMed Weber TK, Conroy J, Keitz B, Rodriguez-Bigas M, Petrelli NJ, Stoler DL, et al. Genome-wide allelotyping indicates increased loss of heterozygosity on 9p and 14q in early age of onset colorectal cancer. Cytogenet Cell Genet. 1999;86:142–7.CrossRefPubMed
23.
Zurück zum Zitat Zhou CZ, Qiu GQ, Zhang F, He L, Peng ZH. Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. World J Gastroenterol. 2004;15(10):1431–5. Zhou CZ, Qiu GQ, Zhang F, He L, Peng ZH. Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. World J Gastroenterol. 2004;15(10):1431–5.
24.
Zurück zum Zitat Slaga TJ. Inhibition of the induction of cancer by antioxidants. Adv Exp Med Biol. 1995;369:167–74.PubMed Slaga TJ. Inhibition of the induction of cancer by antioxidants. Adv Exp Med Biol. 1995;369:167–74.PubMed
25.
Zurück zum Zitat Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol. 1991;2:115–27.PubMed Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol. 1991;2:115–27.PubMed
26.
Zurück zum Zitat Karna E, Pałka JA. Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation. Eur J Pharmacol. 2002;443:1–6.CrossRefPubMed Karna E, Pałka JA. Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation. Eur J Pharmacol. 2002;443:1–6.CrossRefPubMed
27.
Zurück zum Zitat Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.CrossRefPubMed Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.CrossRefPubMed
28.
Zurück zum Zitat Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.CrossRefPubMed Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.CrossRefPubMed
29.
Zurück zum Zitat Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71.CrossRefPubMed Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71.CrossRefPubMed
30.
Zurück zum Zitat Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–7.CrossRefPubMed Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–7.CrossRefPubMed
31.
Zurück zum Zitat Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:858–65.CrossRefPubMed Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:858–65.CrossRefPubMed
32.
Zurück zum Zitat Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. 2002;346:311–20.CrossRefPubMed Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. 2002;346:311–20.CrossRefPubMed
33.
Zurück zum Zitat Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet. 1992;340:1053–8.CrossRefPubMed Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet. 1992;340:1053–8.CrossRefPubMed
34.
Zurück zum Zitat Matsumura Y, Hanbury D, Smith J, Tarin D. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ. 1994;308:619–24.PubMed Matsumura Y, Hanbury D, Smith J, Tarin D. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ. 1994;308:619–24.PubMed
36.
Zurück zum Zitat Ohue M, Tomita N, Monden T, Fujita M, Fukunaga M, Takami K, et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res. 1994;54:4798–804.PubMed Ohue M, Tomita N, Monden T, Fujita M, Fukunaga M, Takami K, et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res. 1994;54:4798–804.PubMed
Metadaten
Titel
DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness
verfasst von
Yuji Toiyama
Yasuhiro Inoue
Hiromi Yasuda
Susumu Saigusa
Takeshi Yokoe
Yoshinaga Okugawa
Koji Tanaka
Chikao Miki
Masato Kusunoki
Publikationsdatum
01.02.2011
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 2/2011
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-010-0318-1

Weitere Artikel der Ausgabe 2/2011

Journal of Gastroenterology 2/2011 Zur Ausgabe

Original Article—Liver, Pancreas, and Biliary Tract

Long-term experience with liver transplantation for hepatocellular carcinoma

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.